Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123280 | 0.83 | SIGMAR1 (0.76) | SIGMAR1HRH3 | |
| SCHEMBL870758 | 0.83 | SIGMAR1 (0.76) | SIGMAR1HRH3 | |
| SCHEMBL27481156 | 0.82 | HRH3 (0.59) | SIGMAR1HRH3BACE1ALDH1A1 | |
| SCHEMBL13015347 | 0.82 | RAB9A (0.52) | SIGMAR1BACE1NPC1TP53RAB9A | |
| SCHEMBL12447952 | 0.81 | RAB9A (0.61) | NPC1TP53RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12447948 | 0.80 | CCR5 (0.61) | NPC1TP53RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12447336 | 0.80 | CCR5 (0.61) | NPC1TP53RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17891160 | 0.80 | RAB9A (0.63) | NPC1TP53RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20139653 | 0.80 | RAB9A (0.63) | NPC1TP53RAB9ASMN1; SMN2ALDH1A1 | |
| Methane SCHEMBL4868105 | 0.79 | SIGMAR1 (0.67) | SIGMAR1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | SIGMAR1 4693/4885HRH3 4767/4885BACE1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.